Gsk (GSK) Gains from Investment Securities (2016 - 2025)
Historic Gains from Investment Securities for Gsk (GSK) over the last 17 years, with Q4 2025 value amounting to -$53.2 million.
- Gsk's Gains from Investment Securities rose 7080.97% to -$53.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$121.0 million, marking a year-over-year increase of 5667.58%. This contributed to the annual value of -$121.3 million for FY2025, which is 785.27% up from last year.
- Gsk's Gains from Investment Securities amounted to -$53.2 million in Q4 2025, which was up 7080.97% from -$9.4 million recorded in Q3 2025.
- Gsk's 5-year Gains from Investment Securities high stood at -$3.8 million for Q2 2023, and its period low was -$588.3 million during Q4 2023.
- In the last 5 years, Gsk's Gains from Investment Securities had a median value of -$39.7 million in 2024 and averaged -$93.1 million.
- Its Gains from Investment Securities has fluctuated over the past 5 years, first soared by 8824.86% in 2021, then tumbled by 87505.41% in 2024.
- Quarter analysis of 5 years shows Gsk's Gains from Investment Securities stood at -$164.5 million in 2021, then tumbled by 47.63% to -$242.8 million in 2022, then plummeted by 142.3% to -$588.3 million in 2023, then surged by 69.02% to -$182.3 million in 2024, then soared by 70.81% to -$53.2 million in 2025.
- Its Gains from Investment Securities stands at -$53.2 million for Q4 2025, versus -$9.4 million for Q3 2025 and -$30.7 million for Q2 2025.